Tuesday, January 2, 2018
Mike Schultz and Frances Johnson are looking to bring the number of metastatic melanoma patients down. Based on discoveries in the lab, the duo started Viewpoint Molecular Targeting, LLC, a company based around a revolutionary radio-pharmaceutical to improve those odds. Read more online.